

Diaceutics PLC - Planned CEO Transition

Peter Keeling stepping back as CEO, Ryan Keeling appointed CEO Designate

Belfast and London, 26 September 2023 - Diaceutics PLC (AIM: DXRX) a leading technology and solutions provider to the pharmaceutical industry, today announces details of its planned CEO transition.

Having co-founded the Company and spent 18 years as its CEO, Peter Keeling has informed the Board of his intention to step back as CEO of Diaceutics on 1 January 2024. He will continue to serve on the Board as an Executive Director, to support the CEO transition. Thereafter, Peter's primary focus will be to accelerate the corporate development of Diaceutics. This will further strengthen Diaceutics leadership position as the primary partner for pharmaceutical companies as they seek to commercialise the new generation of precision therapeutics across a range of disease areas over the coming months and years.

Peter Keeling co-founded Diaceutics in 2005 and has led the growth of the Company from a niche consulting service provider to a high margin, high growth diagnostic commercialisation platform. The Company now serves 21 of the top 30 global pharma companies, with 161 people across Europe and North America and a network of 900 laboratories worldwide. Peter also led the Company's public listing in 2019.

Ryan Keeling, current Chief Innovation Officer, has today been appointed CEO Designate and will become CEO on 1 January 2024. Ryan joined Diaceutics in 2006 and became a member of the Board on IPO in 2019. His current responsibilities as Chief Innovation Officer will be split between the Chief Commercial Officer and Chief Data Officer during the transition period.

Ryan is an expert in the commercialisation of diagnostics and associated technology, with over 17 years' experience in the field. He is the architect of the Company's data capabilities and DXRX platform, leading the development and commercialisation of the Group's technology, including its proprietary data lake. During his tenure with Diaceutics, Ryan has underpinned the Company's growth, holding the key roles of Chief Commercial Officer, Chief Operating Officer and most recently, Chief Innovation Officer where he has led the Group's product innovation, with a near term focus on the development of DXRX.

Deborah Davis, Chair of Diaceutics, commented: *"Peter has been instrumental in making Diaceutics what it is today. Since co-founding the business 18 years ago, Peter has led the evolution of our Company including our IPO in 2019. For nearly two decades, he has been a central force behind Diaceutics' performance and growth and it is reassuring that we will retain the benefit of his wisdom and industry thought leadership at Board level in the future. Ryan has been a core part of our growth and development since he joined the Company in 2006 and is an exceptionally capable leader. I look forward to continuing to work with him as we realise the full scale of the market opportunity, helping our pharma customers identify patients in need of therapy."*

Peter Keeling, CEO of Diaceutics, commented: *"After 18 years building and shaping the business as CEO, I believe Diaceutics has established an important position with our customers as a thought leader in the global precision medicine market. My decision to hand over at this time is made easy knowing how well the Company is now positioned for growth with the talent and motivation of the exceptional team in the business today. Having worked closely with Ryan for more than 17 years, I have complete confidence in him to lead Diaceutics successfully into the future, and I look forward to supporting him and the wider team. It has been my great privilege to work alongside so many leaders from pharmaceutical and laboratory companies, as we built a business which is increasing the treatment opportunities for patients every single day. I would like to take this opportunity to thank everyone at Diaceutics for creating the important business that we are today; and for the support they have provided to me personally throughout these foundational years in Diaceutics."*

Ryan Keeling, CEO Designate, commented: *"Diaceutics is a thriving, growing and global business. I am excited to be taking on the role of CEO and look forward to building on the success that has been created over nearly*

to be taking on the role of CEO and look forward to building on the success that has been created over nearly two decades.

I would like to thank Peter for his leadership and support and the Board for the confidence they have placed in me to lead our exceptional business into the future. I am fortunate to be surrounded by a remarkable and talented team and look forward to executing against the ambitious plans we have for the business."

The Company will today announce its interim results for the six months to 30 June 2023.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer

Tel: +44 (0)28 9040 6500

Ryan Keeling, Chief Executive Officer Designate

investorrelations@diaceutics.com

Nick Roberts, Chief Financial Officer

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

Nick Harland

Kate Hanshaw

Alma

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Matthew Young

Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOASESESIEDSEFU